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Copyright © 2009 JCBN Summary Oxidative stress is frequently considered as a central mechanism of hepatocellular
injury in non-alcoholic steatohepatitis (NASH). The aim of this study was to investigate the
effects of fermented green tea extracts (FGTE) on NASH. Rats were fed a choline-deficient
high-fat diet for 4 weeks to nutritionally generate fatty livers. NASH was induced chemically
by oxidative stress using repeated intraperitoneal injections of nitrite. Rats with NASH devel-
oped steatohepatitis and liver fibrosis after 6-week of such treatment. At 10 weeks, blood and
liver samples were collected from anesthetized animals and assessed for extent of OS injury
and effects of FGTE, by biochemical, histological and histochemical analyses. FGTE reduced
serum levels of liver enzymes, lipid peroxidation and production of mitochondrial reactive
oxygen species. In addition, FGTE showed inhibition of progressions of cirrhosis. Our findings
suggest that our FGTE have strong radical scavenging activity and may be beneficial in the
prevention of NASH progression.
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Introduction
Non-alcoholic steatohepatitis (NASH) is a chronic liver
disease characterized by necroinflamatory activity with
nonspecific inflammatory infiltrates, hepatocyte ballooning
with Mallory’s hyaline and sometimes fibrosis [1]. The “two
hit theory” provides the most widely accepted explanation
describing the progression of NASH. This hypothesis states
that fatty liver, or an excessive fat accumulation in liver
hepatocytes, marks the first stage of NASH development.
The “second hit” is attributed to a factor such as cytokine or
oxidative stress (OS), leading to liver inflammation and
fibrosis [2].
We described previously the development of an animal
model of NASH (Patent application No. PCT/JP2007/52477),
and demonstrated that OS cause extensive hepatic fibrosis
and cirrhosis in this model rats [3]. Therefore, we suggest
that induction of OS as a “second hit” in rats with fatty liver
leads to the development of a NASH-like condition.
There is no effective drug therapy for prevention or
treatment of fatty liver disease, although exercise and diet
improvement to reduce obesity have been suggested.
Therefore, the development of novel supplements or drugs
that prevent non-alcoholic fatty liver disease (NAFLD) or
NASH is urgently required. Only recently has OS beenK. Nakamoto et al.
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postulated to contribute to NASH development. Depletion
of antioxidants such as reduced glutathione (GSH), vitamins
C and E was suggested to occur in NASH patients [4, 5]. To
our knowledge, however, there are few published studies
that have investigated the potential efficacy of antioxidant
supplements against NASH progression. Information
described in reports published by other groups, together
with the data presented in our previous papers, prompt us
to select an excellent antioxidant that could potentially halt
the progression of NASH.
Green tea (Camellia sinensis) is a widely consumed
beverage whose antioxidant activity and other beneficial
health effects have gained considerable notoriety in the
recent years [6]. In the liver diseases, green tea has been
shown to affect hepatic ischemia-reperfusion injury [7],
liver fibrosis [8, 9] and alcohol-induced liver injury [10].
Our green tea water extracts were microbially fermented and
developed to improve flavor, taste, and medicinal function.
The main polyphenols in our fermented green tea extract
(FGTE) preparation were (−)-epigallocatechin (EGC), gallic
acid (GA) and (−)-gallocatechin (GC) as shown in Table 1.
The aim of this study was to determine whether FGTE
prevents NASH progression and to test whether OS provides
“a second hit” and contribute to the development of the
condition.
Materials and Methods
Chemicals
5,5-Dimethyl-l-pyrroline N-oxide (DMPO) was purchased
from Labotech Co. (Tokyo, Japan). 2-(5,5-Dimethyl-2-oxo-
2λ5-[1,3,2]dioxaphosphinan-2-yl (CYPMPO)-2-methyl-3,4-
dihydro-2H-pyrrole 1-oxide was purchased from Radical
Research Inc. (Tokyo, Japan). Dodecyl maltoside (DM) was
from Dojin Laboratories (Kumamoto, Japan). Benzamidine
hydrochloride and sodium nitrate were purchased from
Nacalai Tesque Inc. (Kyoto, Japan). β-NADH was purchased
from Oriental Yeast Co. (Osaka, Japan). Other reagents were
obtained from Wako Pure Chemical Industries (Osaka,
Japan). All chemicals used in our study were of the highest
grade available.
Fermented green tea extract (FGTE) preparation
Ikeda Tohka Industries Co. (Fukuyama, Japan) provided
the green tea leaves used in the present study. After
pasteurizing fresh green tea leaves at 80°C for one hour, the
mixture was fermented using filamentous fungi (Aspergillus
oryzae IFO5238) at 30°C for seven days. The resulting
aqueous green tea extract was dried using a spray drying
process. The resulting powder was stored at −20°C until
analysis.
Animals and experimental design
Male Wistar rats (Shimizu Experimental Animals,
Shizuoka, Japan), weighing 160–170 g and six weeks of age
(purchased from Shimizu Experimental Animals, Shizuoka,
Japan) were used in this study. They were housed in the
Animal Research Center of Okayama University in a
temperature-controlled room (22 ± 1°C) with a relative
humidity of 50 ± 10% and a 12 h light/dark cycle (lights on
at 8:00 a.m.). This study was performed in accordance with
the Guide for Animal Experimentation of the Faculty of
Pharmaceutical Science, Okayama University.
We induced fatty liver in rats by feeding them a choline-
deficient high fat (CDHF) diet (Oriental Yeast) for 4 weeks.
The rats were divided at random into five groups: the
Normal group (n = 6) was fed standard chow for four
weeks), the CDHF group (n = 6) was fed CDHF diet only for
4 weeks; the NASH group (n = 6) was fed CDHF diet for 4
weeks followed by intraperitoneal (i.p.) injections of nitrite
(30 mg/kg/day) for 6 weeks; the FGTE 100 group (n =6 )
was fed CDHF diet for 4 weeks followed by i.p. injections of
nitrite at 30 mg/kg/day for 6 weeks, and also orally admin-
istered FGTE at 100 mg/kg/day (low dose) for 6 weeks;
the FGTE 300 group (n = 6) was fed CDHF diet for 4 weeks
followed by i.p. injections of nitrite at 30 mg/kg/day for 6
weeks, as well as orally administered FGTE at 300 mg/kg/
day (high dose). After six weeks, the rats were fasted
overnight and sacrificed under deep anesthesia. The samples
were prepared to determine OS injury and efficacy of FGTE
administration, by using biochemical and OS markers and
assessment of histological changes. The liver samples were
fixed in 20% formalin or snap-frozen in liquid nitrogen for
histological examination and for our analyses of lipid
peroxidation and antioxidant activity.
Biochemical analyses
The activities of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) in plasma were measured
using commercial enzyme assay kits (Wako Pure Chemical
Table 1. Composition of polyphenols in green tea and FGTE
Data are percentages of solid contents in water extracts.
Components
%
Green tea FGTE
(−)-Catechin (C) — —
(−)-Epicatechin-3-gallate (ECG) 1.3 1.1
(−)-Epigallocatechin (EGC) 13.7 10.2
(−)-Epigallocatechin-3-gallate (EGCG) 9.1 0.6
(−)-Gallocatechin (GC) 1.0 6.9
Total catechin 25.1 18.9
Caffein 6.1 5.1
Gallic acid 0.6 7.2Effects of Fermented Green Tea in Non-alcoholic Steatohepatitis
Vol. 44, No. 3, 2009
241
Industries, Osaka, Japan). The level of plasma alkaline
phosphatase (ALP) was determined using standard assays.
Liver triglycerides
Total lipids were extracted with chloroform-methanol
(2:1) from 100 mg of liver tissue according to the method of
Folch [11]. The extracted lipids were resuspended in t-butyl-
alcohol-methanol-TritonX-100 (2:1:1) and submitted for
measurement using a commercial enzyme assay kit (Wako
Pure Chemical Industries, Osaka, Japan).
Lipid peroxidation in liver homogenates
Liver tissue (100 mg) was homogenized in 10 volumes of
ice-cold Tris-HCl buffer containing 0.25 M sucrose. The
resulting homogenate was centrifuged at 3000 × g for 10 min
at 4°C. The supernatant was used for assays of malondialde-
hyde (MDA) + 4-hexanonenal (4-HNE). MDA + 4-HNE
was measured using a commercial enzyme assay kit (LPO-
586) purchased from OXIS Health Products, Inc. (Portland,
OR).
Plasma SOD-like activity
Plasma superoxide dismutase (SOD)-like activity was
measured using electron paramagnetic resonance (ESR)
spectroscopy. Superoxide radicals were generated using a
hypoxanthine-xanthine oxidase system. CYPMPO was used
as an ESR spectroscopic spin-trapping reagent. The signal
intensity was confirmed by the ratio of the height of the
internal manganese standard signal and the fourth of eight
peaks from the CYPMPO-OOH spin adducts. The condi-
tions used were as follows: magnetic field, 331.5 mT; power,
8 mW; modulation frequency, 9.41 GHz; modulation ampli-
tude, 1 × 0.1 mT; response time, 0.1 s; amplitude, 790; sweep
width, 10 mT; sweep time, 4 min; room temperature [12–14].
Preparation of mitochondria
The liver mitochondria were prepared by differential
centrifugation of the tissue homogenates [15]. In brief, rats
were transcardially perfused with ice-cooled 1.15% KCl
buffer containing 5 mM benzamidine (pH 7.4) via the inferior
vena cava. The liver tissue was then removed (6 g) and
homogenized in 18 volumes ice-cooled 5 mM Tris-HCl
buffer (pH 7.4) containing 0.25 mM sucrose and 100 mM
KCl. The mixture was centrifuged at 2,500 rpm for 10 min
at 4°C. The supernatant was collected and centrifuged at
9,000 × g for 20 min at 4°C. The resulting pellet containing
the mitochondrial fraction was resuspended in the buffer and
stored at −80°C until analysis. The protein concentration
was determined using a BCA kit (Pierce, Rockford, IL) with
bovine serum albumin as a standard.
Reactive oxygen species (ROS) from rat liver mitochondria
DMPO was used for the determination of ROS produced
by rat liver mitochondria. Rat liver mitochondria isolates
(500 μg) were mixed in 0.1 ml potassium phosphate buffer
(pH 7.4) containing 0.1% DM, 5 mM glutamate, 5 mM
malate, 0.1 mM succinate, 0.92 mM DMPO, and 0.1 mM
NADH, incubated for 5 min at 37°C and then measured.
Analyses were performed at room temperature under ambient
atmosphere. Using a manganese signal as an internal
standard, the relative peak height of the second signal
obtained from the DMPO-OH adducts was evaluated. The
conditions were as follows: microwave power, 8 mW;
modulation amplitude width, 0.1 mT; response time, 0.1 s;
scanning time, 4 min; magnetic field, 336.0 ± 5m T  [ 16].
Histological examination
Paraffin-embedded tissues were sectioned at 4 μm thick-
ness and stained with hematoxylin and eosin (H&E),
Masson trichrome for fibrosis. Histological assessment of
tissue morphology was performed using an Olympus light
microscope (Olympus, Tokyo, Japan).
Statistical analyses
Statistical analysis was performed using GraphPad Prism
(Version 4.03; Graph Pad Software, La Jolla, CA) on un-
transformed data. Data were expressed as mean ± standard
error of the mean (SEM). Differences among the groups
were evaluated using Dunnett’s test as a post hoc test. A p
value<0.05 denoted the presence of statistically significant
difference.
Results
Histological evaluation of experimental liver samples
Representative histological sections of livers from each
group are shown in Fig. 1. Severe liver atrophy was
observed in NASH livers. The livers of CDHF-fed rats
were significantly greater in size compared to MF-chow fed
rats. Conversely, adding FGTE prevented this effect, but had
no effect on the features of fatty liver (data not shown).
Histopathological examination of liver tissues stained with
H&E showed hepatic macrovesicular steatosis in all CDHF-
fed rats (Fig. 1a–d). We evaluated the effects of FGTE on
liver fibrogenesis in the different treatment groups. No
fibrosis was noted in the livers of rats fed standard chow
(Normal) compared with those fed CDHF alone. In the
NASH rats, steatosis, liver fibrosis, and necrosis were quite
advanced. Liver fibrosis was clearly attenuated in all groups
treated with FGTE (Fig. 1e–h).
Effects of FGTE on body weight, liver index, and plasma
biochemical parameters
There were no differences in body weights between
NASH and FGTE-treated rats. In contrast, the body weights
of rats fed normal or CDHF alone were greater during theK. Nakamoto et al.
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entire experimental period. Wet liver weights and liver
indexes of NASH rats were lower than those of the FGTE
group and CDHF alone group (p<0.05 vs Normal rats,
p<0.01 vs CDHF-fed rats). Food consumption was about
20 g/day while water intake was about 20 ml/day.
With regard to liver function test, AST, ALT, and ALP
levels were significantly higher in NASH rats compared
with rats of the CDHF group. In the FGTE 100 group, the
liver enzymes improved compared with NASH, but the
changes were not significant. FGTE supplementation at
Fig. 1. Histological evaluation of liver samples of rats of various groups. Effects of FGTE on liver structure were examined by
hematoxylin and eosin staining in Normal (a), CDHF (b), NASH (c), and NASH + FGTE 300 mg/kg (d) rats. Effects of FGTE
on liver fibrosis were examined by Masson Trichrome staining in Normal (e), CDHF (f), NASH (g), and NASH + FGTE
300 mg/kg (h). Data show typical results. Scale bar = 200 µm.Effects of Fermented Green Tea in Non-alcoholic Steatohepatitis
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300 mg/kg significantly improved AST and ALP compared
with the NASH group, although these parameters were still
higher than the normal and CDHF groups (Table 2).
Effects of FGTE on plasma antioxidant activity
The levels of plasma SOD-like activity were significantly
lower in NASH rats (p<0.01, vs Normal). NASH rats sup-
plemented with FGTE at 300 mg/kg showed a significant
improvement and had high plasma SOD-like activity that
was comparable to that found in NASH rats. This was not
the case, however, for rats supplemented with 100 mg/kg
FGTE (p<0.01 vs NASH rats, Fig. 2).
Effects of FGTE on liver triglyceride level
Triglyceride levels were higher in the livers of NASH rats
and rats fed CDHF alone, compared with the control
(Fig. 3). However, supplementation of 300 mg/kg FGTE,
but not 100 mg/kg FGTE, decreased these levels in such
rats (p<0.01 vs NASH rats).
Effects of FGTE on lipid peroxidation in liver homogenates
To investigate whether FGTE can prevent lipid peroxida-
tion, we measured the formation of MDA and 4-HNE in
liver tissue. The levels of MDA and 4-HNE were signifi-
cantly higher in NASH rats (p<0.01, vs the CDHF group,
p<0.01 versus the CDHF group). However, they were not
different between CDHF and Normal rats. Supplementation
of 300 mg/kg FGTE resulted in reduction of MDA and 4-
HNE levels (p<0.01 vs NASH rats, Fig. 4).
Table 2. Effects of FGTE on body weight, wet liver weight and biochemical markers
Each value is the mean ± SEM of 6 rats.
*p<0.05, **p<0.01, compared with NASH. #p<0.01, compared with Normal.
FGTE: fermented green tea extract, CDHF: choline-deficient high-fat. NASH: CDHF + OS, FGTE 100: NASH + FGTE 100 mg/kg,
FGTE 300: NASH + FGTE 300 mg/kg.
Normal CDHF
NASH
0 100 300
FGTE (mg/kg/day, p.o.)
Body weight (g) 356.0 ± 28.3 249.0 ± 25.9 241.5 ± 29.0 225.1 ± 4.9 250.3 ± 8.8
Wet liver weiht (g) 9.4 ± 4.6 14.4 ± 3.0 11.2 ± 2.6# 10.4 ± 0.5 14.3 ± 2.0*
Liver index (%) 
(liver wet weight/body × 100)
2.6 ± 0.8 5.6 ± 0.6 4.9 ± 0.9# 4.6 ± 0.2 5.7 ± 0.4*
Biochemical marker (plasma)
AST (IU/L) 54.2 ± 2.5 178.8 ± 23.3 290.7 ± 7.9# 243.8 ± 18.2 235.2 ± 21.7*
ALT (IU/L) 15.0 ± 1.1 21.9 ± 4.6 33.91 ± 2.4# 24.8 ± 1.3 14.1 ± 1.3
ALP (Released p-nitrophenol, mM) 0.1 ± 0.1 0.3 ± 0.1 0.5 ± 0.1# 0.5 ± 0.1 0.3 ± 0.1**
Fig. 2. Effects of FGTE on plasma SOD-like activity in Normal, CDHF, NASH, FGTE 100 and FGTE 300 groups using an ESR. ESR
spectra of the CYPMPO-OOH spin adducts obtained from hypoxanthine-xanthine oxidase systems in Normal (a), CDHF (b),
NASH (c), NASH + FGTE 100 mg/kg (d) and NASH + FGTE 300 mg/kg (e) rats. Each value is the mean ± SEM of 6 rats.
*p<0.05, **p<0.01, compared with NASH. #p<0.01, compared with Normal.K. Nakamoto et al.
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Effects of FGTE on mitochondrial ROS production
Finally, we evaluated the effects of FGTE on mitochon-
drial ROS production. Signals derived from DMPO-OH
adducts in our ESR analysis were detected in the liver
mitochondria of all groups. The highest signal intensities,
however, were found in rats of the NASH group. In contrast,
no significant difference was found between CDHF-fed
rats and Normal group. FGTE (300 mg/kg) administration,
however, caused a significant decrease in detectable levels
of liver mitochondrial ROS (p<0.01 vs NASH rats, Fig. 5).
Discussion
The goal of this study was to investigate whether FGTE
can prevent NASH progression and to propose a novel
functional food for the prevention of NASH. Our results
clearly showed that supplements of FGTE prevent liver
dysfunction, increase plasma antioxidant, decrease liver
triglyceride level and suppressing mitochondrial ROS
production in NASH model rats. The results suggest that
FGTE delays the progression of fatty liver to fibrosis.
Consistent with the present study, it has been reported that
EGCG attenuates steatohepatitis induced by high fat diet
[17]. In addition, green tea extracts protect against obesity-
triggered by NAFLD in leptin-deficient obese mice [18].
However, one of the striking differences between the above
report and our present study is the contents of EGCG. The
EGCG content in their study was high whereas FGTE in our
study was not detected by HPLC analysis because of the
decrease in the fermentation process. Additionally, the
fermentation process caused a 12-fold increase in GA
content and a 6.9-fold increase in GC content, but vitamin C
levels were lower compared to those in regular green tea
extracts. Despite containing less EGCG and vitamin C than
green tea extracts, our FGTE had a strong radical scavenging
activity, which was at least equal to that of typical tea
extracts and vitamin C (data not shown). These results
suggest that FGTE seems to prevent NASH progression
through mechanism(s) different to those of EGCG.
NAFLD is exacerbated by impaired antioxidant pathways.
This effect is more pronounced in NASH than in fatty
liver. Furthermore, depletion of antioxidants such as GSH,
vitamins C and E, and low plasma antioxidant activity are
also reported in NASH [19]. These changes result in
increased lipid peroxidation in NASH patients [20].
Therefore, we hypothesized that treatment with an anti-
oxidant may prevent NASH progression. Our results showed
that the administration of FGTE increased plasma SOD-like
activity and decreased liver concentrations of MDA and 4-
HNE (Fig. 2 and 4). These results suggest that FGTE supple-
mentation can reset the balance between pro- and anti-
Fig. 3. Effects of FGTE on triglycerides level in the liver of
Normal, CDHF, NASH, NASH + FGTE 100 mg/kg and
NASH + FGTE 300 mg/kg groups. Each value is the
mean ± SEM of 6 rats. *p<0.05, compared with NASH.
##p<0.01, compared with Normal.
Fig. 4. Effects of FGTE on lipid peroxide levels in the liver of
Normal, CDHF, NASH, NASH + FGTE 100 mg/kg and
NASH + FGTE 300 mg/kg groups. Each value is the
mean ± SEM of 6 rats. **p<0.01, compared with NASH.
##p<0.01, compared with Normal.
Fig. 5. Effects of FGTE on liver mitochondrial ROS production
of the Normal, CDHF, NASH, NASH + FGTE 100 mg/
kg and NASH + FGTE 300 mg/kg group. Each value is
the mean ± SEM of 6 rats. *p<0.05, **p<0.01, compared
with NASH. #p<0.01, compared with Normal.Effects of Fermented Green Tea in Non-alcoholic Steatohepatitis
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oxidants. What is the mechanism of FGTE-induced in-
creased plasma antioxidant activity? One potential mecha-
nism is up-regulation of Cu-Zn SOD protein. However, no
significant difference was found in Cu-Zn SOD protein
expression between NASH and FGTE-treated rats (data not
shown). This finding suggests that FGTE could have
superior effects over regular green tea extracts. It is possible
that the fermentation process of green tea extract changes
its components and augments its antioxidative effects.
Therefore, so many polyphenols in FGTE can play the role
in protect body against NASH.
At present, however, the exact ingredient of FGTE most
responsible for the observed effects in our study is unknown.
Therefore, further studies are necessary to isolate and
identify this ingredient from our FGTE. Nevertheless, the
results emphasize the potential beneficial effects of foods
with radical scavenging activity in NASH.
To clarify the mechanisms underlying the effects of
FGTE on NASH, we examined triglyceride levels in the liver
and ROS productions in the liver mitochondria. The high
fat accumulations in the liver promote the β-oxidation in
mitochondria, and follow to induce excess ROS production
and result in mitochondrial dysfunction. Therefore, the
mitochondria are the most important intracellular source of
ROS in NASH [21]. In this study, FGTE administration
reduced liver triglyceride levels (Fig. 3), suggesting that
FGTE administration may regulate the excess triglyceride
accumulation in the liver of NASH rat. According to the
recent report, inhibiting TG synthesis improve hepatic
steatosis but exacerbates liver damage and fibrosis in mice
model of NASH [22]. Therefore, we consider that it is the
most important for the NASH prevention to control both the
hepatic steatosis and oxidative stress.
ROS production results in the depletion of mitochondrial
DNA, up-regulation of uncoupling protein 2, reduced
activity of respiratory chain complexes, impaired mitochon-
drial β-oxidation, resulting in mitochondrial dysfunction and
abnormal mitochondrial morphology [23–25]. We also
demonstrated previously increased ROS production by the
mitochondria in rats with NASH, indicating that accumula-
tion of excess ROS and fatty acids in the liver could cause
damage of the mitochondrial membranes. Accordingly, we
expected that administration of FGTE would prevent mito-
chondrial dysfunction caused by induction of excessive ROS
and fatty acids. Our results indicate that FGTE-treated rats
with NASH-like disease state showed restoration of normal
levels of mitochondrial ROS production (Fig. 5). Moreover,
our work indicated that the increased mitochondrial ROS
productions might cause progression of fatty liver disease to
NASH.
In summary, in NASH rats, oxidative stress damage is
induced by pro-excessive ROS production and failure of
antioxidant defence mechanisms. It is possible that oxidative
stress damage is associated with progression of NASH. At
this stage, however, further studies are warranted to assess
serial changes in mitochondrial function and liver architec-
ture in NASH liver, determine the mechanisms of NASH
improvement by and anti-fibrotic activity of FGTE. More-
over, further studies are required to understand how FGTE
prevent mitochondrial dysfunction and fibrosis in advanced
NASH.
Conclusion
In conclusion, we demonstrated in the present study that
the antioxidant activity of FGTE can prevent the progression
of NASH by suppressing the production of mitochondrial
ROS.
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